Healthcare Equipment and Supplies
Company Overview of Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. provides solutions for screening, diagnosing, monitoring, and confirming diseases for the transfusion medicine community and laboratories worldwide. It offers integrated clinical chemistry and immunoassay testing systems, chemistry systems, immunodiagnostic systems, and automation solutions that streamline and standardize laboratory workflow. The company also provides donor screening solutions, such as Ortho Summit System, a system for screening assays, automation, and information management; T-cruzi ELISA test system, an enzyme-linked immunosorbant assay for the qualitative detection of antibodies to trypanosoma cruzi in human serum and plasma specimens; and...
1001 US Highway 202
Raritan, NJ 08869
Founded in 1974
Key Executives for Ortho-Clinical Diagnostics, Inc.
Chairman and Chief Executive Officer
Executive Vice President and General Counsel
Executive Vice President for Commercial
Compensation as of Fiscal Year 2015.
Ortho-Clinical Diagnostics, Inc. Key Developments
Ortho Clinical Diagnostics Appoints Kristie Bouryal as Chief Corporate Brand and Communications Officer
Aug 3 15
Ortho Clinical Diagnostics announced that Kristie Bouryal has been named Chief Corporate Brand and Communications Officer, effective immediately. As the newest member of the firm's executive leadership team, Bouryal will lead the company's worldwide corporate brand and communication strategies as the organization builds on its transition to an independent company by adding sites in countries outside the U.S. She will report to Chairman and Chief Executive Officer Dr. Martin Madaus. Most recently, she was Chief Marketing and Communications Officer for Marsh, a global leader in insurance broking and risk management. Across Marsh's global footprint, Bouryal led all aspects of marketing, communications, and thought leadership content development.
Sphere Medical Holding plc Completes the Data Package for Proxima 4 and Submit to Ortho-Clinical Diagnostics, Inc
Jul 22 15
Sphere Medical Holding plc announced that the company has completed the Data Package for Proxima 4, an important prerequisite for submitting the technical files and design dossiers for CE-marking as well as fulfilling its obligations to submit the Data Package to Ortho-Clinical Diagnostics, Inc. ('OCD;) under the collaboration agreement between OCD and Sphere Medical. The Data Package has recently been completed by Sphere and submitted to OCD within the originally anticipated time frame set out in the Collaboration Agreement. Sphere will continue with the finalisation of the submission process for the CE-marking, whilst OCD will now decide on whether it elects to exercise its option to enter into negotiations with Sphere Medical with regard to exclusive commercialisation rights of Proxima 4.
Ortho-Clinical Diagnostics, Inc. Receives FDA 510k Clearance for VITROS Chemistry Products HbA1c Reagent Kit, an Enhanced Diabetes Testing Assay
Jun 18 15
Ortho-Clinical Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. The test is to be used as an aid in the diagnosis of diabetes, as an aid in identifying patients who may be at risk for developing diabetes mellitus, and for the monitoring of long-term blood glucose control in individuals with diabetes mellitus. The VITROS Chemistry Products HbA1c Reagent Kit offers operational and performance enhancements over the company's currently marketed VITROS Chemistry Products d%A1c Reagent Kit, including higher throughput and simplified calibration. The design of the VITROS HbA1c assay allows its use in patients with hemoglobin variants S, C, D, and E traits. The new assay is now available and will replace the VITROS Chemistry Products d%A1c Reagent Kit, which will eventually be discontinued. A false high or low HbA1c value caused by a clinically silent hemoglobin variant may lead to over or under treatment. The design of the VITROS HbA1c assay allows its use in patients with hemoglobin variants S, C, D and E traits. In addition, the method is unaffected by the presence of chemically modified hemoglobin. Approximately 7% of the world's population are heterozygous carriers of hemoglobinopathies. Among diabetic patients, more than 12 million worldwide are estimated to have a hemoglobin disorder. In the U.S., the four most common variants are Hb S, C, E, and D. HbE is found primarily in people from Southeast Asia and is now encountered quite commonly in the U.S. HbD Punjab is found most commonly in the Punjab region of India and is also encountered in the U.S.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|